Ointment |
Trade name, availability |
Mode of activity |
Range of activity |
Main use |
Side effects/additional considerations |
Mupirocin |
Bactroban |
Inhibitor of bacterial protein synthesis |
Gram‐positive organisms, especially Staphylococcus aureus
|
Impetigo, elimination of S aureus from anterior nares |
Anaphylaxis reported |
Bacitracin |
Ingredient of triple antibiotic ointment |
Interferes with bacterial cell wall synthesis |
Gram‐positive organisms |
Impetigo, furunculosis, pyodermas |
Cross‐sensitisation with neomycin |
Polymixin B |
Available singly, combined with bacitracin or in triple antibiotic ointment |
Disrupts bacterial cell membrane and increases cell permeability |
Gram‐negative organisms, including Pseudomonas aeruginosa, Enterbacter species and Escherichia coli
|
Bacterial conjunctivitis |
Limited spectrum of activity |
Neomycin |
Available alone, or as ingredient of triple antibiotic ointment |
Interferes with bacterial cell wall synthesis |
Aerobic Gram‐positive and Gram‐negative bacilli |
Prevention of infection in superficial abrasions, cuts or burns |
Allergic contact dermatitis |
Polymixin B, neomycin and bacitracin |
Triple antibiotic ointment |
Combination of mechanisms |
Range of Gram‐positive and Gram‐negative organisms |
Prevention of infection in superficial abrasions, cuts or burns |
Allergic contact dermatitis |
Erythromycin |
Eryacne |
Inhibitor of bacterial protein synthesis |
Gram‐positive cocci |
Acne |
Low incidence of sensitisation |
Chloramphenicol |
Chlormycetin or Chlorsig |
Disrupts bacterial cell membrane |
Wide range of Gram‐positive and Gram‐negative organisms |
Bacterial conjunctivitis |
Aplastic anaemia |